They established a gefitinib-resistant cell line model with MET gene amplification by exposing a gefitinib-sensitive lung cancer cell line (HCC827) with an activating EGFR mutation (exon 19 E746_A750 del) to increasing concentrations of gefitinib. This evidence concerns the gene EGFR and lung carcinoma.